Literature DB >> 18683105

Golimumab, a fully human monoclonal antibody against TNFalpha.

Gabor Hutas1.   

Abstract

Centocor Inc and licensees Schering-Plough Corp, Mitsubishi Tanabe Pharma Corp and Janssen Pharmaceutical KK are developing golimumab, a fully human mAb antibody against TNFalpha, for the potential treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS) and ulcerative colitis. Golimumab is currently in phase III clinical trials for RA, PsA and AS and preliminary data have shown an improvement in a number of physical functions, disease activity, productivity and quality-of-life measurements.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18683105

Source DB:  PubMed          Journal:  Curr Opin Mol Ther        ISSN： 1464-8431


  11 in total

Review 1.  Golimumab and malignancies: true or false association?

Authors:  Ines Zidi; Aicha Bouaziz; Wissem Mnif; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2010-04-07       Impact factor: 3.064

Review 2.  TNF-alpha and its inhibitors in cancer.

Authors:  Inès Zidi; Souhir Mestiri; Aghleb Bartegi; Nidhal Ben Amor
Journal:  Med Oncol       Date:  2009-03-11       Impact factor: 3.064

3.  Variability in Golimumab Exposure: A 'Real-Life' Observational Study in Active Ulcerative Colitis.

Authors:  Iris Detrez; Erwin Dreesen; Thomas Van Stappen; Annick de Vries; Els Brouwers; Gert Van Assche; Séverine Vermeire; Marc Ferrante; Ann Gils
Journal:  J Crohns Colitis       Date:  2016-01-06       Impact factor: 9.071

4.  Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease.

Authors:  Satoshi Tanida; Tsutomu Mizoshita; Takashi Mizushima; Makoto Sasaki; Takaya Shimura; Takeshi Kamiya; Hiromi Kataoka; Takashi Joh
Journal:  J Clin Biochem Nutr       Date:  2011-02-26       Impact factor: 3.114

Review 5.  Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.

Authors:  Jihye Park; Jae Hee Cheon
Journal:  Gut Liver       Date:  2018-11-15       Impact factor: 4.519

6.  Biologics in dermatologic therapy - an update.

Authors:  Arijit Coondoo
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

Review 7.  Golimumab (anti-TNF monoclonal antibody): where we stand today.

Authors:  Ana Teresa Melo; Raquel Campanilho-Marques; João Eurico Fonseca
Journal:  Hum Vaccin Immunother       Date:  2020-12-28       Impact factor: 3.452

Review 8.  Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties.

Authors:  Mahmoud Mosli; Mohammad Al Beshir; Bandar Al-Judaibi; Turki Al-Ameel; Abdulaziz Saleem; Talat Bessissow; Subrata Ghosh; Majid Almadi
Journal:  Saudi J Gastroenterol       Date:  2014 Mar-Apr       Impact factor: 2.485

Review 9.  Golimumab for the treatment of ulcerative colitis.

Authors:  Mark Löwenberg; Nanne Kh de Boer; Frank Hoentjen
Journal:  Clin Exp Gastroenterol       Date:  2014-03-12

10.  Golimumab: early experience and medium-term outcomes from two UK tertiary IBD centres.

Authors:  Mark A Samaan; Polychronis Pavlidis; Jonathan Digby-Bell; Emma L Johnston; Angad Dhillon; Ramesh Paramsothy; Abisoye O Akintimehin; Lucy Medcalf; Guy Chung-Faye; Patrick DuBois; Ioannis Koumoutsos; Nick Powell; Simon H C Anderson; Jeremy Sanderson; Bu' Hussain Hayee; Peter M Irving
Journal:  Frontline Gastroenterol       Date:  2017-10-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.